Please login to the form below

Not currently logged in
Email:
Password:

DOAA news in brief

Our weekly round-up of news affecting healthcare advertising

Vet all DTC before it circulates, AZ tells FDA

AstraZeneca has proposed that all direct-to-consumer (DTC) drug adverts should be submitted to the US Food and Drug Administration (FDA) for review prior to use. The Anglo-Swedish company made the recommendation in a letter to the FDAís public hearing on consumer-directed promotion of regulated medical products. The FDA is currently considering revising the rules about safety and risk information prescription drug commercials should include and whether all consumer-directed advertisements must be reviewed before they are circulated. Pharmaceutical companies have recently been the subject of highly critical FDA warning letters with respect to existing promotional campaigns.

Drug promotions examined at FDA hearing

US prescription drug adverts have come under the microscope as US Food and Drug Administration (FDA) hearings over the future of direct-to-consumer (DTC) advertising have got under way. At the hearings, Diana Zuckerman, president of the National Research Center for Women & Families showed several ads for Merckís withdrawn painkiller Vioxx depicting women in idyllic situations. She said the FDA should consider regulating image selection "because imagery can be as powerful as any wording". Several speakers attacked off-label promotions of antidepressants. Peter Lurie of health advocacy group Public Citizen showed the 11-member panel an internet-based promotion for the acne drug Differin that promised teenagers free music downloads in exchange for signing up at the website, and for getting a prescription and refilling it.

2nd September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics